{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:22:36Z","timestamp":1784568156620,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The t(11;14)(q13;32) is a common chromosome translocation in multiple myeloma (MM), but its prognostic value remains controversial. Immunoglobulin light chain amyloidosis is commonly secondary to multiple myeloma, which can rapidly cause heart failure and high mortality. We aimed to investigate the prevalence of secondary cardiac amyloidosis in MM patients with t(11;14) and to evaluate its impact on survival outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively identified 52 MM patients with t(11;14) in our center between October 2015 and April 2022. The associations between cardiac amyloidosis and clinical and biological parameters were statistically analyzed, and the impacts of concomitant of cardiac amyloidosis on survival and prognosis of MM patients with t(11;14) were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Concomitant presence of cardiac amyloidosis was observed in 15 (28.8%) of all cases. Patients with cardiac amyloidosis had significantly higher NT-proBNP (<jats:italic>p<\/jats:italic> = 0.002) and higher hs-cTnT (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), while the patients without cardiac amyloidosis had higher percentage of bone marrow plasma cells (<jats:italic>p<\/jats:italic> = 0.027), higher incidence of hemoglobin &amp;lt;80 g\/L (<jats:italic>p<\/jats:italic> = 0.021) and bone destruction (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). The median overall survival (OS) for all patients was 33.4 months after a median follow-up of 23.8 months. The amyloidosis group showed a significantly shorter OS than the non-amyloidosis group (15.3 vs. 41.8 months, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Besides, patients harboring NT-proBNP &amp;gt;1,800 pg\/ml (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) or hs-cTnT \u226740 pg\/ml (<jats:italic>p<\/jats:italic> = 0.001) or light chain (LC) only isotype (<jats:italic>p<\/jats:italic> = 0.033) had a significantly shorter mean OS compared with patients with lower NT-proBNP or hs-cTnT or other M-protein isotype. Univariate analyses showed that NT-proBNP &amp;gt;1,800 pg\/ml, hs-cTnT \u226740 pg\/ml, LC only isotype, and concomitant presence of cardiac amyloidosis were independently associated with shorter OS, while NT-proBNP &amp;gt;1,800 pg\/ml still retained the prognostic value for OS in multivariate analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The t(11;14) MM patients with coexisting cardiac amyloidosis may represent a distinct clinical entity that confers a poor outcome. These findings may have important clinical and biological implications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.994384","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T09:28:45Z","timestamp":1662110925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma"],"prefix":"10.3389","volume":"9","author":[{"given":"Jinghua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingji","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe Francophone du my\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p163;q32), and\u221217p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International myeloma working group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.bbmt.2013.05.017","article-title":"Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma","volume":"19","author":"Sasaki","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia."},{"key":"B13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk Lymphoma."},{"key":"B16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8","article-title":"Primary systemic amyloidosis with delayed progression to multiple myeloma","volume":"82","author":"Rajkumar","year":"1998","journal-title":"Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0889-8588(05)70122-2","article-title":"Amyloidosis","volume":"13","author":"Gertz","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.bmt.1705395","article-title":"Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?","volume":"38","author":"Bahlis","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00277-008-0554-0","article-title":"Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor","volume":"88","author":"Vela-Ojeda","year":"2009","journal-title":"Ann Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021","volume":"11","author":"Hasib Sidiqi","year":"2021","journal-title":"Blood Cancer J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3109\/13506120009146438","article-title":"Amyloidosis and cardiac involvement","volume":"151","author":"Cacoub","year":"2000","journal-title":"Ann Med Interne."},{"key":"B22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0049-0172(05)80006-X","article-title":"Amyloidosis: prognosis and treatment","volume":"24","author":"Gertz","year":"1994","journal-title":"Semin Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on amyloid and amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/archinte.148.3.662","article-title":"Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement","volume":"148","author":"Pellikka","year":"1988","journal-title":"Arch Intern Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cncr.33206","article-title":"Prognostic impact of t(11;14) in multiple myeloma: black and white or shades of gray?","volume":"127","author":"Chakraborty","year":"2020","journal-title":"Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.994384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T09:28:49Z","timestamp":1662110929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.994384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2022.994384"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.994384","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"994384"}}